866-997-4948(US-Canada Toll Free)

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 96 Pages

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016, provides in depth analysis on Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) Overview 9
Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.Therapeutics Development 9
Therapeutics Development 10
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Stage of Development 10
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Therapy Area 11
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Indication 12
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Companies 16
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Products under Development by Universities/Institutes 21
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development 29
Beta Pharma Inc 29
Eli Lilly and Company 30
FLX Bio, Inc. 31
G1 Therapeutics Inc 32
Jiangsu Hengrui Medicine Co Ltd 33
Novartis AG 34
Onconova Therapeutics Inc 35
Pfizer Inc 36
Teijin Pharma Ltd 37
ViroStatics srl 38
XuanZhu Pharma Co Ltd 39
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Drug Profiles 40
abemaciclib - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
BPI-1178 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
FLX-925 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
G-1T28 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
G-1T38 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
GZ-381 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
MMD-37K - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ON-123300 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
palbociclib - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
ribociclib succinate - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
SHR-6390 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers and Warts - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Dormant Projects 79
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Discontinued Products 80
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Featured News & Press Releases 81
Nov 16, 2016: PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizers IBRANCE (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer 81
Nov 10, 2016: IBRANCE (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer 82
Nov 01, 2016: Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (Ribociclib) Plus Letrozole as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer 84
Nov 01, 2016: Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer 84
Oct 08, 2016: Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care 85
Oct 05, 2016: Lilly Presents New Data on Abemaciclib At ESMO 2016 86
Sep 16, 2016: Pfizer Receives Positive CHMP Opinion For IBRANCE (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe 87
Aug 10, 2016: Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib 87
Aug 03, 2016: Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer 88
Jul 13, 2016: European breast cancer trial opens in Ireland 89
Jul 06, 2016: Study Tests New Breast Cancer Drug In African American Women 90
Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy 91
May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data 92
May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types 92
May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96

List of Tables
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Products under Development by Companies, H2 2016 (Contd..2) 19
Products under Development by Companies, H2 2016 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by Beta Pharma Inc, H2 2016 29
Pipeline by Eli Lilly and Company, H2 2016 30
Pipeline by FLX Bio, Inc., H2 2016 31
Pipeline by G1 Therapeutics Inc, H2 2016 32
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 33
Pipeline by Novartis AG, H2 2016 34
Pipeline by Onconova Therapeutics Inc, H2 2016 35
Pipeline by Pfizer Inc, H2 2016 36
Pipeline by Teijin Pharma Ltd, H2 2016 37
Pipeline by ViroStatics srl, H2 2016 38
Pipeline by XuanZhu Pharma Co Ltd, H2 2016 39
Dormant Projects, H2 2016 79
Discontinued Products, H2 2016 80

List of Figures
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Top 10 Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *